专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

US20110263541A1 KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS 有权
标题翻译：激酶抑制剂及其作为药物代用品
公开(公告)号：US20110263541A1
公开(公告)日：2011-10-27
申请号：US13095526
申请日：2011-04-27
申请人： Ying LUO , Fang SHU , Shudong WANG
发明人： Ying LUO , Fang SHU , Shudong WANG
IPC分类号： A61K31/506 , C07D471/04 , A61K31/5377 , A61K31/635 , A61P35/00 , A61P29/00 , A61P7/00 , A61P11/00 , A61P37/08 , A61P11/06 , A61P37/06 , A61P25/28 , A61P19/08 , A61P3/00 , C07D403/04
CPC分类号： C07D403/04 , C07D471/04
摘要： Described herein are compounds that are inhibitors of one or more protein kinases. Also described are pharmaceutical compositions and medicaments that include the compounds described herein. Also described herein are methods of using such protein kinase inhibitors, alone and in combination with other compounds, for conditions or diseases mediated or dependent upon protein kinases.
摘要翻译：本文描述的是一种或多种蛋白激酶的抑制剂的化合物。还描述了包括本文所述的化合物的药物组合物和药物。本文还描述了使用这种蛋白激酶抑制剂单独和与其它化合物组合用于介导或依赖于蛋白激酶的病症或疾病的方法。

22. 发明申请

US20090290591A1 RELIABILITY PROCESSING METHODS AND SYSTEMS IN THE NETWORKING OF METRO ETHERNET NETWORK PROVIDING MULTI-SERVICE 有权
标题翻译：网络提供多业务网络的可靠性处理方法与系统
公开(公告)号：US20090290591A1
公开(公告)日：2009-11-26
申请号：US12536030
申请日：2009-08-05
申请人： Xuejiang ZHANG , Guangyu SUN , Feng GANG , Ming WEI , Xindong TENG , Hongsen MAO , Shudong WANG
发明人： Xuejiang ZHANG , Guangyu SUN , Feng GANG , Ming WEI , Xindong TENG , Hongsen MAO , Shudong WANG
IPC分类号： H04L12/56
CPC分类号： H04L45/00 , H04L45/28 , H04L45/586
摘要： A reliability processing method and system in networking of Metro Ethernet Network providing multi-service are provided. The method includes: establishing a Virtual Router Redundancy Protocol (VRRP) group with at least two service control gateways, establishing network connections between an access device (UPE) and the service control gateways in the Virtual Router Redundancy Protocol group by a Virtual Private LAN Service (VPLS); establishing Layer 2 service and Layer 3 service connections between an active service control gateway and the Access device after active and standby service control gateways in the Virtual Router Redundancy Protocol group are determined according to a processing result of a Virtual Router Redundancy Protocol message, and performing Layer 2 service and Layer 3 service processing. With the present invention, when the MAN service is in fault, all the Layer 2 and Layer 3 services may be switched to the standby service control gateway quickly, and the switching may be on the order of milliseconds. Therefore, the reliability of the Layer 2 and Layer 3 services of the MAN may be sufficiently guaranteed, and the overhead of the system may be reduced significantly.
摘要翻译：提供了提供多业务的城域以太网网络的可靠性处理方法和系统。该方法包括：通过至少两个服务控制网关建立虚拟路由冗余协议（VRRP）组，通过虚拟专用局域网服务在虚拟路由器冗余协议组中建立接入设备（UPE）与业务控制网关之间的网络连接（VPLS）; 根据虚拟路由器冗余协议消息的处理结果确定虚拟路由器冗余协议组中的主备服务控制网关之后，在活动业务控制网关与接入设备之间建立二层业务和三层业务连接，并执行二层业务和三层业务处理。根据本发明，当MAN业务处于故障状态时，所有二层和三层业务都可以快速切换到备用业务控制网关，并且交换可能在几毫秒左右。因此，可以充分保证城域网二层和三层业务的可靠性，同时可以显着降低系统开销。

23. 发明授权

US07576091B2 Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases 失效
标题翻译：能够抑制蛋白激酶的噻唑并恶唑氮和咪唑并喹唑啉化合物
公开(公告)号：US07576091B2
公开(公告)日：2009-08-18
申请号：US11326805
申请日：2006-01-06
申请人： Campbell McInnes , Mark Peter Thomas , Shudong Wang , Neil McIntyre , Nicholas Westwood , Peter Martin Fischer
发明人： Campbell McInnes , Mark Peter Thomas , Shudong Wang , Neil McIntyre , Nicholas Westwood , Peter Martin Fischer
IPC分类号： A01N43/54 , A61K31/505 , C07D239/00 , C07D471/00 , C07D487/00 , C07D491/00
CPC分类号： C07D413/04
摘要： A compound of formula 1, or a pharmaceutically acceptable salt thereof, wherein: X is S, O, or NH; “a” is a single bond; or “a” is a double bond and one of R3 and R4, and one of R5 and R6 are absent; R1 is H; or is selected from an alkyl group, a cycloalkyl group, a heteroaryl group, an aralkyl group, CO-alkyl, SO2-alkyl, CO2R13 and an aryl group, each of which optionally contains one or more heteroatoms, and is optionally substituted with one or more groups selected from R8 and R9; R2 is H, R8, or an alkyl group optionally substituted with one or more R8 groups; R3, R4, R5, and R6 are each independently selected from H, R8, an alkyl group and an alkenyl group, wherein said alkyl and alkenyl groups are optionally substituted with one or more R8 groups; or R3 and R4, and/or R5 and R6 together represent ═O; R7 is H, R8, NH(CH2)nR9, CO(CH2)nR9, NHCO(CH2)nR9, O(CH2)nR9, or an alkyl or phenyl group, each of which is optionally substituted with one or more groups selected from R8 and R9; R8 is OR10, NR10R11, halogen, CF3, NO2, COR10, CN, COOR10, CONR10R11, SO2R10 or SO2NR10R11; R9 is a saturated or unsaturated 5- or 6-membered cyclic group optionally containing one or more heteroatoms selected from N, O and S, and optionally substituted with one or more R8 groups; R10, R11, R12 and R13 are each independently H or a hydrocarbyl group; and n is 0, 1, 2 or 3. Further aspects of the invention relate to pharmaceutical compositions comprising compounds of formula 1, and the therapeutic use thereof in the treatment of proliferative disorders, viral disorders, CNS disorders, diabetes, stroke and cardiovascular disorders.
摘要翻译：式1的化合物或其药学上可接受的盐，其中：X是S，O或NH; “a”是单一债券; 或“a”为双键，R3和R4之一，R5和R6之一不存在; R1是H; 或选自烷基，环烷基，杂芳基，芳烷基，CO-烷基，SO 2 - 烷基，CO 2 R 13和芳基，其各自任选含有一个或多个杂原子，并且任选地被一个或更多选自R8和R9的基团; R2是H，R8或任选被一个或多个R 8基团取代的烷基; R3，R4，R5和R6各自独立地选自H，R8，烷基和烯基，其中所述烷基和烯基任选被一个或多个R 8基团取代; 或R 3和R 4，和/或R 5和R 6一起表示-O; R 7是H，R 8，NH（CH 2）n R 9，CO（CH 2）n R 9，NHCO（CH 2）n R 9，O（CH 2）n R 9或烷基或苯基，其各自任选被一个或多个选自 R8和R9; R8为OR10，NR10R11，卤素，CF3，NO2，COR10，CN，COOR10，CONR10R11，SO2R10或SO2NR10R11; R 9是任选地含有一个或多个选自N，O和S的杂原子，并且任选地被一个或多个R 8基团取代的饱和或不饱和的5-或6-元环基团; R 10，R 11，R 12和R 13各自独立地为H或烃基; 本发明的其它方面涉及包含式1化合物的药物组合物及其治疗增殖性疾病，病毒性疾病，中枢神经系统疾病，糖尿病，中风和心血管疾病的治疗用途。

24. 发明申请

US20080318954A1 Compounds 审中-公开
标题翻译：化合物
公开(公告)号：US20080318954A1
公开(公告)日：2008-12-25
申请号：US10588372
申请日：2005-02-07
申请人： Kenneth Duncan , Darren Gibson , Shudong Wang , Daniella I. Zheleva , Peter Martin Fischer
发明人： Kenneth Duncan , Darren Gibson , Shudong Wang , Daniella I. Zheleva , Peter Martin Fischer
IPC分类号： A61K31/505 , A61P19/08 , C07D401/02 , A61K31/5355 , A61K31/444 , C07D413/02 , C07D417/04
CPC分类号： C07D417/04 , C07D417/14
摘要： The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salts thereof, wherein: Z1: 1 is N or CH; Z2 and Z3 are each independently N or CR7; R1, R2, R3, R4, R5, R6, and R7 are each independently H, R8, or R9; each R8 is independently a hydrocarbyl group; and each R9 is independently halo, NO2, alkoxy, CN, CF3, S03H, SO2NR10R11, S02R12, NR13R14(CH2)aCOOR15, (CH2)bCONR16R17, (CH2)cCOR18 or (CH2)dOH; a, b, c and d are each independently 0, 1 2 3 or 4; R10-18 are each independently H or alkyl; provided that when R1 and R2 are both H, Z1 is CH; or Z2 is N; or Z1 is CH and Z2 is N; and wherein the compound is other than 4-(4,5-dimethylthiazol-2-yl)-N-(3,4,5trimethoxyphenyl)-2-pyrimidineamine or 4-(5-(2-hydroxyethyl)-4-methylthiazol-2-yl)N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine. Further aspects relate to the use of compounds of formula (I) in the preparation of a medicament for treating one or more disorders selected from a proliferative disorder, a viral disorder, a CNS disorder, diabetes, stroke or alopecia.
摘要翻译：本发明涉及式（I）化合物或其药学上可接受的盐，其中：Z1：1是N或CH; Z2和Z3各自独立地为N或CR7; R 1，R 2，R 3，R 4，R 5，R 6和R 7各自独立地为H，R 8或R 9; 每个R 8独立地是烃基; 并且每个R 9独立地为卤素，NO 2，烷氧基，CN，CF 3，SO 3 H，SO 2 NR 10 R 11，SO 2 R 12，NR 13 R 14（CH 2）a COOR 15，（CH 2）b CONR 16 R 17，（CH 2）c COR 18或（CH 2） a，b，c和d各自独立地为0，1 2 3或4; R 10-18各自独立地为H或烷基; 条件是当R1和R2都是H时，Z1是CH; 或Z2为N; 或Z 1为CH，Z 2为N; 并且其中所述化合物不是4-（4,5-二甲基噻唑-2-基）-N-（3,4,5-三甲氧基苯基）-2-嘧啶胺或4-（5-（2-羟乙基）-4-甲基噻唑-2-基）吡啶-2-基）N-（3,4,5-三甲氧基苯基）-2-嘧啶胺。其它方面涉及式（I）化合物在制备用于治疗选自增殖性病症，病毒病症，CNS病症，糖尿病，中风或脱发的一种或多种病症的药物中的用途。

25. 发明授权

US07427627B2 N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds 有权
标题翻译： N-（4-（4-甲基噻唑-5-基）嘧啶-2-基）-N-苯胺作为抗增殖化合物
公开(公告)号：US07427627B2
公开(公告)日：2008-09-23
申请号：US11433312
申请日：2006-05-11
申请人： Shudong Wang , Christopher Meades , Andrew Osnowski , Gavin Wood , Peter Martin Fischer
发明人： Shudong Wang , Christopher Meades , Andrew Osnowski , Gavin Wood , Peter Martin Fischer
IPC分类号： C07D417/04 , A61K31/506
CPC分类号： C07D417/04
摘要： The present invention relates to 2-substituted 4-heteroaryl-pyrimidines, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin-dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders such as cancer, leukaemia, psoriasis and the like.
摘要翻译：本发明涉及2-取代的4-杂芳基嘧啶，其制备方法，含有它们的药物组合物及其作为细胞周期蛋白依赖性激酶（CDK）抑制剂的用途，因此可用于治疗增殖性疾病如癌症，白血病，牛皮癣等。

26. 发明授权

US07337731B2 Conjoined folding table 有权
标题翻译：连结折叠桌
公开(公告)号：US07337731B2
公开(公告)日：2008-03-04
申请号：US11022223
申请日：2004-12-23
申请人： Jiawei Mu , Shudong Wang
发明人： Jiawei Mu , Shudong Wang
IPC分类号： A47B3/04
CPC分类号： A47B3/00
摘要： A conjoined folding table includes a table plane and plane support frames, wherein under the table plane are disposed two groups of identical support frames. Each group of plane support frames includes two support legs, two slide support rods, a slide block, two slant support rods, a pull rod, a stay bar, two plane support traverse tubes, a pivotal member, and a U-shaped hinge. The slide support rod is connected to the support leg via a slide block, and the upper end of the slide support rod is movably hinged with the plane support traverse tube. The lower ends of the two slide support rods are rotatably connected via a rotary member, or one end of slide support rod is connected to the support leg via a slide block, and the other end is connected to the plane support traverse via a slide block and is provided with a cross support rod.
摘要翻译：联合折叠台包括桌面和平面支撑框架，其中在桌面下面设置两组相同的支撑框架。每组平面支撑框架包括两个支撑腿，两个滑动支撑杆，滑块，两个倾斜支撑杆，拉杆，撑杆，两个平面支撑横向管，枢转构件和U形铰链。滑动支撑杆通过滑块连接到支撑腿，滑动支撑杆的上端与平面支撑横动管可移动地铰接。两个滑动支撑杆的下端通过旋转构件可旋转地连接，或者滑动支撑杆的一端通过滑动块连接到支撑腿，另一端通过滑块连接到平面支撑横向并设有十字支撑杆。

27. 发明申请

US20070185134A1 Inhibitors of cyclin dependent kinases as anti-cancer agent 审中-公开
标题翻译：细胞周期蛋白依赖性激酶抑制剂作为抗癌剂
公开(公告)号：US20070185134A1
公开(公告)日：2007-08-09
申请号：US11507929
申请日：2006-08-21
申请人： Peter Fischer , Shudong Wang , Gavin Wood
发明人： Peter Fischer , Shudong Wang , Gavin Wood
IPC分类号： A61K31/506 , C07D403/02
CPC分类号： C07D403/04
摘要： The present invention relates to 2-substituted 4-heteroaryl-pyrimidines, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin-dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders such as cancer, leukaemia, psoriasis and the like.
摘要翻译：本发明涉及2-取代的4-杂芳基嘧啶，其制备方法，含有它们的药物组合物及其作为细胞周期蛋白依赖性激酶（CDK）抑制剂的用途，因此可用于治疗增殖性疾病如癌症，白血病，牛皮癣等。

28. 发明申请

US20060264628A1 Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases 失效
公开(公告)号：US20060264628A1
公开(公告)日：2006-11-23
申请号：US11326805
申请日：2006-01-06
申请人： Campbell McInnes , Mark Thomas , Shudong Wang , Neil McIntyre , Nicholas Westwood , Peter Fischer
发明人： Campbell McInnes , Mark Thomas , Shudong Wang , Neil McIntyre , Nicholas Westwood , Peter Fischer
IPC分类号： C07D498/02
CPC分类号： C07D413/04
摘要： A compound of formula 1, or a pharmaceutically acceptable salt thereof, wherein: X is S, O, or NH; “a” is a single bond; or “a” is a double bond and one of R3 and R4, and one of R5 and R6 are absent; R1 is H; or is selected from an alkyl group, a cycloalkyl group, a heteroaryl group, an aralkyl group, CO-alkyl, SO2-alkyl, CO2R13 and an aryl group, each of which optionally contains one or more heteroatoms, and is optionally substituted with one or more groups selected from R8 and R9; R2 is H, R8, or an alkyl group optionally substituted with one or more R8 groups; R3, R4, R5, and R6 are each independently selected from H, R8, an alkyl group and an alkenyl group, wherein said alkyl and alkenyl groups are optionally substituted with one or more R8 groups; or R3 and R4, and/or R5 and R6 together represent ═O; R7 is H, R8, NH(CH2)nR9, CO(CH2)nR9, NHCO(CH2)nR9, O(CH2)nR9, or an alkyl or phenyl group, each of which is optionally substituted with one or more groups selected from R8 and R9; R8 is OR10, NR10R11, halogen, CF3, NO2, COR10, CN, COOR10, CONR10R11, SO2R10 or SO2NR10R11; R9 is a saturated or unsaturated 5- or 6-membered cyclic group optionally containing one or more heteroatoms selected from N, O and S, and optionally substituted with one or more R8 groups; R10, R11, R12 and R13 are each independently H or a hydrocarbyl group; and n is 0, 1, 2 or 3. Further aspects of the invention relate to pharmaceutical compositions comprising compounds of formula 1, and the therapeutic use thereof in the treatment of proliferative disorders, viral disorders, CNS disorders, diabetes, stroke and cardiovascular disorders.

29. 发明申请

US20060241297A1 Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors 审中-公开
公开(公告)号：US20060241297A1
公开(公告)日：2006-10-26
申请号：US11339059
申请日：2006-01-25
申请人： Shudong Wang , Christopher Meades , Darren Gibson , Peter Fischer
发明人： Shudong Wang , Christopher Meades , Darren Gibson , Peter Fischer
IPC分类号： C07D417/14
CPC分类号： C07D417/14
摘要： The present invention relates to compounds of formula I, or pharmaceutically acceptable salts thereof, wherein: (A) “a” is a single bond and “b” is a double bond; R1 and R2 are each independently as defined below; R10 is absent; or (B) “a” is a double bond and “b” is a single bond; R1 is oxygen; R2 is as defined below; and R10 is H or alkyl; X is S, O, NH, or NR7; Y is N or CR8; one of Z1, Z2, and Z3 is N or N+Ra and the remainder are each independently CR7; R1, R2, R5 and R6 are each independently R7; R3 and R4 are each independently R8; each R7 is independently H, halogen, NRbRc, ORd or a hydrocarbyl group optionally substituted by one or more R9 groups; each R8 is independently H or (CH2)nR9, where n is 0 or 1; each R9 is independently selected from H, halogen, NO2, CN, Re, NHCORf, CF3, CORg, NRhRi, CONRjRk, SO2NRlRm, SO2Rn, ORp, OCH2CH2ORq, morpholine, piperidine and piperazine; and Ra-q are each independently H or alkyl, wherein said alkyl group is optionally substituted by one or more R9 groups; where the compound is other than [4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2-yl]-pyridin-2-yl-amine and 4-[4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-imidazol-5-yl]-N-4-pyridinyl-2-pyrimidinamine. Further aspects of the invention relate to the use of compounds of formula I in the treatment of proliferative disorders, viral disorders, CNS disorders, strokes, alopecia and/or diabetes.

30. 发明授权

US06992169B2 Carrier based drug delivery system 失效
公开(公告)号：US06992169B2
公开(公告)日：2006-01-31
申请号：US10210660
申请日：2002-07-31
申请人： Peter M. Fischer , Shudong Wang , Nikolai Zhelev
发明人： Peter M. Fischer , Shudong Wang , Nikolai Zhelev
IPC分类号： A61K38/08 , A61K38/10 , C07K7/06 , C07K7/08
CPC分类号： A61K47/62
摘要： The present invention relates to a novel drug delivery system of use in the improved delivery of drug therapeutic agents into target cells. The system comprises a drug moiety linked to a carrier moiety wherein the carrier moiety comprises a homeobox peptide or a fragment or derivative thereof.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式